volume 93, issue 0, P3-P-343 2020
DOI: 10.1254/jpssuppl.93.0_3-p-343
View full text
|
|
Share

Abstract: Immune checkpoint inhibitors such as anti-PD-1 antibody and anti-PD-L1 antibody have recently been approved for the treatment of melanoma or non-small cell lung cancer. In this study, we examined the anti-tumor effect of anti-PD-L1 antibody with low molecular weight compound. Mice were subcutaneously inoculated with a mouse cancer cell line. They were allocated into the control,anti-PD-L1 antibody, low molecular weight compound and their combination treatment groups. Anti-PD-L1 antibody was administered intrap…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals